The current TNM (tumor, nodes, metastases) staging system for human hepatoc
ellular carcinoma (HCC) has been challenged since a new T staging system wa
s proposed to correlate the staging group with patient outcome after curati
ve liver resection. The new T staging system proposed T1 as no vascular inv
asion, small size (less than or equal to 5 cm), and solitary tumor. T2 was
defined as the presence of one of the following factors: size greater than
5 cm, vascular invasion, or multiple tumors; T3 as the presence of two of t
he above three factors; and T4, the presence of all three factors. A total
of 323 patients undergoing curative partial hepatectomy for HCC were studie
d. Kaplan-Meier survival analysis was used to evaluate the postoperative ou
tcome. The new T staging showed good correlation between the staging group
and patient outcome. The 1-year disease-free survival (DFS) rate and overal
l survival (OS) rate were 80.0% and 87.8% for stage 1 (n = 115), 67.6% and
81.6% for stage 2 (n = 136), 40.0% and 58.0% for stage 3 (n = 58), and 21.4
% and 42.8% for stage 4 (n = 14), respectively. The 3-year DFS rate and OS
rate were 61.0% and 64.5% for stage 1, 37.8% and 50.7% for stage 2, 21.4% a
nd 29.8% for stage 3, and 21.4% and 34.3% for stage 4, respectively. When a
nalyzed using the current International Union Against Cancer (UICC) patholo
gic (p) TNM staging system, the 1-year and 3-year DFS rates were 86.2% and
64.0% for stage 1 (n = 30), 73.9% and 50.0% for stage 2 (n = 182), and 46.8
% and 22.3% for stage 3 (n = 111), respectively. Our results showed that, w
hile both staging systems allow clear stratification of patients into progn
ostic groups, the modified TNM system is not superior to the UICC pTNM syst
em in predicting survival of HCC patients after curative partial hepatectom
y. A larger scale, multicenter study may be needed to test the revised TNM
system.